Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combination for Newly Diagnosed AITL
NCT07168317Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in angioimmunoblastic T-cell lymphoma (AITL), sponsored by The Affiliated Hospital of Xuzhou Medical University. Started Aug 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT07168317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168317.